Nasioudis D, et al. - A total of 4,811 subjects diagnosed with stage I mucinous ovarian cancer (MOC) between 2004 and 2015 were recognized from the U.S National Cancer Database by the experts in order to determine the advantage of adjuvant chemotherapy for cases with MOC. Chemotherapy was provided to 1,488 (30.9%) subjects, 20.2% and 60.2% for those with stage IA/IB and IC respectively. Stage IC, larger tumor size, and high tumor grade were correlated with the receipt of chemotherapy. No variation in overall survival among subjects who did (n = 1,322) and did not (n = 2,920) receive chemotherapy. No variation was remarked after the stratification by substage. The administration of chemotherapy was not correlated with better survival, following controlling for substage, patient age, type of insurance, tumor grade, the performance of lymphadenectomy and the presence of co-morbidities. Hence, no association of receiving chemotherapy with survival advantage could be ascertained in a large cohort of patients with stage I MOC.